MX2018001040A - Moleculas de acido nucleico artificiales. - Google Patents
Moleculas de acido nucleico artificiales.Info
- Publication number
- MX2018001040A MX2018001040A MX2018001040A MX2018001040A MX2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A MX 2018001040 A MX2018001040 A MX 2018001040A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- artificial nucleic
- utr
- utr element
- acid molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Abstract
La invención se refiere a una molécula de ácido nucleico artificial que comprende al menos un marco de lectura abierto y al menos un elemento de región 3´ no traducida (elemento 3´-UTR) y/o al menos un elemento de región 5´ no traducida (elemento 5´-UTR), en donde la molécula de ácido nucleico artificial se caracteriza por eficiencia de traducción alta. La eficiencia de traducción es contribuida, al menos en parte, por el elemento 5´-UTR o el elemento 3´-UTR, o tanto el elemento 5´-UTR como el elemento 3´-UTR. La invención se refiere además al uso de esta molécula de ácido nucleico artificial en la terapia génica y/o vacunación genética. Además, se proporcionan elementos 3´-UTRs y elementos 5´-UTRs novedosos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2015001755 | 2015-08-28 | ||
PCT/EP2016/001417 WO2017036580A1 (en) | 2015-08-28 | 2016-08-22 | Artificial nucleic acid molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001040A true MX2018001040A (es) | 2018-06-15 |
Family
ID=54064264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001040A MX2018001040A (es) | 2015-08-28 | 2016-08-22 | Moleculas de acido nucleico artificiales. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20180237786A1 (es) |
EP (2) | EP4108774A1 (es) |
JP (2) | JP7304155B2 (es) |
KR (1) | KR102645398B1 (es) |
CN (2) | CN114381470A (es) |
AU (1) | AU2016316439B2 (es) |
BR (1) | BR112018001995A2 (es) |
CA (1) | CA2992801A1 (es) |
DK (1) | DK3341482T3 (es) |
ES (1) | ES2924739T3 (es) |
MX (1) | MX2018001040A (es) |
SG (1) | SG10201913629VA (es) |
WO (1) | WO2017036580A1 (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
AU2014220957A1 (en) | 2013-02-22 | 2015-07-30 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
SG10201801431TA (en) | 2013-08-21 | 2018-04-27 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
CA3179824A1 (en) | 2014-06-25 | 2015-12-30 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US11149278B2 (en) | 2014-12-12 | 2021-10-19 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
EP3283059B1 (en) | 2015-04-13 | 2024-01-03 | CureVac Manufacturing GmbH | Method for producing rna compositions |
EP3283125B1 (en) | 2015-04-17 | 2021-12-29 | CureVac Real Estate GmbH | Lyophilization of rna |
US11384375B2 (en) | 2015-04-30 | 2022-07-12 | Curevac Ag | Immobilized poly(n)polymerase |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
CN107530448A (zh) | 2015-05-20 | 2018-01-02 | 库瑞瓦格股份公司 | 包含长链rna的干粉组合物 |
US10760070B2 (en) | 2015-05-29 | 2020-09-01 | Curevac Real Estate Gmbh | Method for producing and purifying RNA, comprising at least one step of tangential flow filtration |
US11608513B2 (en) | 2015-05-29 | 2023-03-21 | CureVac SE | Method for adding cap structures to RNA using immobilized enzymes |
CA2990202A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
DK3319622T3 (da) | 2015-12-22 | 2020-05-04 | Curevac Ag | Fremgangsmåde til fremstilling af rna-molekylesammensætninger |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
US11723967B2 (en) | 2016-02-17 | 2023-08-15 | CureVac SE | Zika virus vaccine |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
US11478552B2 (en) | 2016-06-09 | 2022-10-25 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
EP3500295A2 (en) | 2016-08-19 | 2019-06-26 | CureVac AG | Rna for cancer therapy |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
US20200085944A1 (en) | 2017-03-17 | 2020-03-19 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
SG10202110491PA (en) | 2017-03-24 | 2021-11-29 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
AU2018256867A1 (en) | 2017-04-27 | 2019-11-14 | The Johns Hopkins University | Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus |
AU2018256877B2 (en) | 2017-04-28 | 2022-06-02 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
JP7355731B2 (ja) | 2017-08-16 | 2023-10-03 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
RU2020115287A (ru) * | 2017-10-19 | 2021-11-19 | Куревак Аг | Новые молекулы искусственных нуклеиновых кислот |
EP3707271A1 (en) | 2017-11-08 | 2020-09-16 | CureVac AG | Rna sequence adaptation |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
US11525158B2 (en) | 2017-12-21 | 2022-12-13 | CureVac SE | Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA |
US20210361761A1 (en) | 2018-04-05 | 2021-11-25 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
CN112292395A (zh) | 2018-04-17 | 2021-01-29 | 库瑞瓦格股份公司 | 用于疫苗接种的新型rsv rna分子和组合物 |
EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
CN113453707A (zh) | 2018-12-21 | 2021-09-28 | 库瑞瓦格股份公司 | 用于疟疾疫苗的rna |
WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
CN110812366B (zh) * | 2019-11-18 | 2023-11-17 | 珠海丽凡达生物技术有限公司 | 一种可用于激素补充的mRNA药物及其制备方法 |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
IL293571A (en) | 2020-02-04 | 2022-08-01 | Curevac Ag | Corona virus vaccine |
CN111494631B (zh) * | 2020-04-27 | 2022-10-18 | 北京大学人民医院 | 一种原发性免疫性血小板减少症miRNA标记物及其应用 |
AU2021279312A1 (en) | 2020-05-29 | 2022-12-15 | CureVac SE | Nucleic acid based combination vaccines |
EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
US20240066114A1 (en) | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
EP4267178A1 (en) | 2020-12-22 | 2023-11-01 | CureVac SE | Rna vaccine against sars-cov-2 variants |
US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
CN117377491A (zh) | 2021-03-26 | 2024-01-09 | 葛兰素史克生物有限公司 | 免疫原性组合物 |
EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
AU2022284878A1 (en) | 2021-06-04 | 2024-01-18 | Translate Bio, Inc. | Assay for quantitative assessment of mrna capping efficiency |
CA3223855A1 (en) * | 2021-06-24 | 2022-12-29 | Seung Su Han | Non-natural 5?-untranslated region and 3?-untranslated region and use thereof |
WO2023008793A1 (ko) * | 2021-07-27 | 2023-02-02 | 에스케이바이오사이언스(주) | 단백질 발현을 위한 mrna와 이를 위한 주형 |
AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
CN115404238A (zh) * | 2021-12-22 | 2022-11-29 | 江苏拓弘康恒医药有限公司 | 高翻译稳定性BDNF mRNA的设计和制备方法 |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
CN114540307A (zh) * | 2022-02-16 | 2022-05-27 | 多莱泌生物科技(武汉)有限公司 | 一种靶向肝脏的工程化外泌体制备方法 |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
CN117487809B (zh) * | 2023-12-29 | 2024-03-19 | 艾斯拓康医药科技(北京)有限公司 | 一种优化的5`utr序列及其应用 |
CN117535295B (zh) * | 2024-01-09 | 2024-04-26 | 艾斯拓康医药科技(北京)有限公司 | 一种优化的3`utr序列及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
EP1800697B1 (de) | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
WO2008112127A2 (en) * | 2007-03-08 | 2008-09-18 | Switchgear Genomics | Functional arrays for high throughput characterization of regulatory elements in untranslated regions of genes |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
EP2955230A1 (en) | 2010-07-30 | 2015-12-16 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
CA2859452C (en) * | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
KR102186497B1 (ko) * | 2012-03-27 | 2020-12-04 | 큐어백 아게 | 인공 핵산 분자 |
RU2660565C2 (ru) * | 2012-03-27 | 2018-07-06 | Кьюрвак Аг | Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top |
CA2868996A1 (en) * | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
SG10201801428RA (en) * | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
DK3090053T3 (en) | 2013-12-30 | 2019-02-25 | Curevac Ag | Artificial nucleic acid molecules |
SG10201906673WA (en) | 2014-12-30 | 2019-09-27 | Curevac Ag | Artificial nucleic acid molecules |
-
2016
- 2016-08-22 MX MX2018001040A patent/MX2018001040A/es unknown
- 2016-08-22 CN CN202210036661.4A patent/CN114381470A/zh active Pending
- 2016-08-22 EP EP22176444.2A patent/EP4108774A1/en active Pending
- 2016-08-22 BR BR112018001995A patent/BR112018001995A2/pt active Search and Examination
- 2016-08-22 US US15/755,739 patent/US20180237786A1/en active Pending
- 2016-08-22 JP JP2018511127A patent/JP7304155B2/ja active Active
- 2016-08-22 ES ES16759979T patent/ES2924739T3/es active Active
- 2016-08-22 WO PCT/EP2016/001417 patent/WO2017036580A1/en active Application Filing
- 2016-08-22 CA CA2992801A patent/CA2992801A1/en active Pending
- 2016-08-22 AU AU2016316439A patent/AU2016316439B2/en active Active
- 2016-08-22 SG SG10201913629VA patent/SG10201913629VA/en unknown
- 2016-08-22 EP EP16759979.4A patent/EP3341482B1/en active Active
- 2016-08-22 DK DK16759979.4T patent/DK3341482T3/da active
- 2016-08-22 CN CN201680049973.1A patent/CN108026537B/zh active Active
- 2016-08-22 KR KR1020187008732A patent/KR102645398B1/ko active IP Right Grant
-
2021
- 2021-08-16 JP JP2021132110A patent/JP7245878B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
BR112018001995A2 (pt) | 2018-09-18 |
EP3341482A1 (en) | 2018-07-04 |
ES2924739T3 (es) | 2022-10-10 |
CN114381470A (zh) | 2022-04-22 |
JP2018529329A (ja) | 2018-10-11 |
JP2021192613A (ja) | 2021-12-23 |
WO2017036580A1 (en) | 2017-03-09 |
AU2016316439B2 (en) | 2022-02-24 |
DK3341482T3 (da) | 2022-08-15 |
KR102645398B1 (ko) | 2024-03-07 |
RU2018110872A (ru) | 2019-10-01 |
AU2016316439A1 (en) | 2018-02-08 |
SG10201913629VA (en) | 2020-03-30 |
EP3341482B1 (en) | 2022-07-06 |
JP7245878B2 (ja) | 2023-03-24 |
CN108026537A (zh) | 2018-05-11 |
KR20180038564A (ko) | 2018-04-16 |
JP7304155B2 (ja) | 2023-07-06 |
CN108026537B (zh) | 2022-02-08 |
CA2992801A1 (en) | 2017-03-09 |
EP4108774A1 (en) | 2022-12-28 |
US20180237786A1 (en) | 2018-08-23 |
RU2018110872A3 (es) | 2020-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018001040A (es) | Moleculas de acido nucleico artificiales. | |
MX2020003245A (es) | Moleculas artificiales de acido nucleico. | |
MX2017008670A (es) | Moleculas artificiales de acido nucleico novedosas. | |
MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
MX358706B (es) | Moleculas de acido nucleico artificiales que comprenden un top 5´utr. | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
MX2019002345A (es) | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. | |
WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2018011384A (es) | Arn de replicacion en trans. | |
MX2020006065A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
IL280652A (en) | Nucleic acid molecules and their use for non-viral gene therapy | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
NZ752941A (en) | Frataxin expression constructs | |
MX2021004391A (es) | Proteinas inteinas y usos de las mismas. |